Application No. PCT/EP03/03349 Attorney Docket No. PG4786USW

## In the Abstract:

Please substitute the attached Abstract, which has been placed on a separate sheet of paper according to US practice, as required under 37 CFR 1.72(b).

## **ABSTRACT**

## MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY A HETEROCYCLYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS

Certain compounds of formula (I):

$$R^{1} \xrightarrow{Y} \underset{R^{3}}{\overset{O}{\underset{|A}{\bigvee}}} \underset{R^{4}}{\overset{O}{\underset{|A}{\bigvee}}} \underset{R}{\overset{O}{\underset{|A}{\bigvee}}}$$

wherein:

R<sup>1</sup> is substituted or unsubstituted heterocyclyl;

Y is  $-(CR_{na}R_{nb})_n$ -;

 $R_{na}$  and  $R_{nb}$  are each independently hydrogen or  $C_{1\text{-}6}$ alkyl;

n is an integer from 1 to 5;

 $\ensuremath{R^2}\xspace$  is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

 $m R^3$  and  $m R^4$  each independently are hydrogen or  $m C_{1-6}$ alkyl; and salts and solvates thereof are CCR-3 antagonists and thus are indicated to be useful in therapy.